NOVEL BIOMARKERS AND
DRUG TARGETS WITHIN REACH

At Drug Target ID, we integrate genome-wide omics data in a specific biological construct to identify biomarkers and unlock scientific leads for drug target identification and development.

Unbiased & Curated

For all of our analyses we start from unbiased, large omics data sets. During our analyses we take into account research biases and functional annotation errors. In addition, all the mechanisms and interactions that we identify are manually curated and based on experimental evidence rather than predictions.

Biological Construct

We are driven by data, but value the underlying biology even more! In this respect, our molecular landscape model allows for the integration of (putative) mechanisms, risk factors, biomarkers and drug targets in a single disease model. Therefore, as opposed to a “bioinformatics-only” approach, our method draws upon the extensive expertise of our team to put the findings into a broader biological construct (e.g. specific tissues and cell types), which greatly enhances the accuracy of our method.

Target Specificity

Our method enables the identification of disease mechanisms, risk factors, biomarkers and especially drug targets. We can rank these targets based on 5 criteria of specificity, which leads to truly novel leads for treatment development.

WHO ARE WE?

Drug Target ID was established in 2012 in Nijmegen, the Netherlands and works at the interface between the scientific community and the pharmacological industry.